Antimicrobial Peptide Screening Service
Antimicrobial Peptide Screening Service is a specialized drug discovery platform designed to accelerate the identification and optimization of novel antimicrobial peptides (AMPs). With the global escalation of antimicrobial resistance (AMR), conventional antibiotics are increasingly insufficient against multidrug-resistant bacteria, fungal infections, and emerging pathogens. AMPs, as part of the innate immune defense system across many organisms, provide a promising alternative due to their rapid membrane-disrupting mechanisms, broad-spectrum activity, and relatively low propensity for resistance development.
This service is built to support early-stage discovery as well as lead optimization, enabling researchers to efficiently navigate vast peptide sequence space and identify functional candidates with therapeutic potential.
High-Throughput Screening of Large Peptide Space
A core feature of this service is the ability to screen extremely large and structurally diverse peptide libraries. Through high-throughput biological assays, millions to trillions of peptide variants can be evaluated for antimicrobial activity against clinically relevant microbial strains.
Screening is typically performed across multiple pathogen categories, including Gram-positive bacteria, Gram-negative bacteria, drug-resistant clinical isolates, and selected fungal species. This multi-organism evaluation strategy ensures that identified peptides demonstrate broad applicability rather than strain-specific effects.
Assay outputs are designed to capture both potency and functional killing kinetics, allowing researchers to distinguish between bacteriostatic and bactericidal mechanisms. This is particularly important for identifying peptides capable of rapid membrane disruption, one of the key advantages of AMP-based therapeutics.
